Skip to main content
SpringerLink
Log in

The Development of Cancer Vaccines for the Treatment of Metastatic Melanoma

  • Conference paper
Progress in Anti-Cancer Chemotherapy

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 3))

  • 61 Accesses

Abstract

Immunization against pathogens induces humoral as well as cellular immune responses. While the former is directed toward extra-cellular invaders, the latter is directed toward proteins produced by pathogens following their infection of permissive cells. Like other intracellular proteins, viral products are enzymatically degraded into short peptides (9–11 amino acids in length) and presented on the surface of infected cells in association with Major Histocompatibility Complex (MHC) class I molecules: a requirement for T cell recognition. Vaccines aimed at prevention of disease might be particularly effective because they can arm the host with powerful neutralizing antibodies against subsequent infections which results in a dramatic reduction in the load of pathogen reaching the target cell. After the pathogen is hidden in the host’s cells, the immune system relies predominantly on T cell function. Clearing of the infection will at this point depend on the balance between the efficiency of the T cell response and the protective strategies adopted by the pathogen [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zinkernagel RM (1996) Immunology taught by viruses. Science 271:173

    Article  PubMed  CAS  Google Scholar 

  2. Yewdell JW, Bennink JR (1990) The binary logic of antigen processing and presentation to T cells. Cell 62:203

    Article  PubMed  CAS  Google Scholar 

  3. Old LJ, Chen YT (1998) New Paths in Human Cancer Serology. J Exp Med 187:1163

    Article  PubMed  CAS  Google Scholar 

  4. Restifo NP, Wunderlich JR (1996) Principles of tumor immunity: biology of cellular immune responses. In: De Vita VT, Hellmans, Rosenberg SA (eds) Biologic therapy of cancer. JB Lippincott Co, Philadelphia, p 3

    Google Scholar 

  5. Knuth A, Danowski B, Oettgen HF, Old LJ (1984) T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T- cell cultures. Proc Natl Acad Sci USA 81:3511

    Article  PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, D.R. Parkinson, C.A. Seipp, J.H. Einhorn, D.E. White (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159

    Article  PubMed  CAS  Google Scholar 

  7. Burnet FM (1970). The concept of immunological surveillance. Prog Exp Tumor Res 13:1

    PubMed  CAS  Google Scholar 

  8. Kawakami Y, Rosenberg SA (1996). T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 15:179

    Article  PubMed  CAS  Google Scholar 

  9. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175

    Article  PubMed  CAS  Google Scholar 

  10. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol.Today 18:267

    Article  PubMed  CAS  Google Scholar 

  11. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller M, Yannelli JR, Appella E, Rosenberg SA (1995) Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an Immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154:2257

    PubMed  CAS  Google Scholar 

  12. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA (1996). Differential anti-MART-l/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 19:266

    Article  CAS  Google Scholar 

  13. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, and Marincola FM (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART- 1/Melan A. Cancer J Sci Am 3:37

    PubMed  CAS  Google Scholar 

  14. Salgaller ML, Marincola FM, Cormier JN, Rosenber SA (1996) Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptides. Cancer Res 56:4749

    PubMed  CAS  Google Scholar 

  15. Rosenberg SA, Yang JC, Schwartzentmber D, Hwu P, Marincola FC, Topalian SL, Restifo NP, Dufour E, Schwartzberg L, Spiess P, Wunderlich J, Parkhurst MR, Kawakami Y, Seipp C, Einhorn JH, White D (1998) Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321

    Article  PubMed  CAS  Google Scholar 

  16. Mc CE C.M. Mc (1996) Systemic chemotherapy for the treatment of metastatic melanoma. Semin.Oncol 23:744

    Google Scholar 

  17. Marincola FM, Rosenberg SA (1995) Biologic Therapy with Interleukin-2. Clinical Apphcations-Melanoma. In: De Vita VT, Hellmans, Rosenberg SA (eds) Biologic Therapy of Cancer. JB Lippincott Company, Philadelphia, PA, p 250

    Google Scholar 

  18. Rosenberg SA (1997) Keynote address: perspective on the use of Interleukin-2 in cancer treatment. Cancer J Sci Am 3:S2

    PubMed  Google Scholar 

  19. Marincola FM (1994) Interleukin-2. Biol Ther Cancer Updates 4 (3):1

    Google Scholar 

  20. Lotze MT (1991) Interleukin-2: Basic principles. In: De Vita VT, Hellmans, Rosenberg SA (eds) Biologic Therapy of Cancer. JB Lippincott Co, Philadelphia, p 123

    Google Scholar 

  21. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentmber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White D (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine- activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622

    Article  PubMed  CAS  Google Scholar 

  22. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.

    Article  PubMed  CAS  Google Scholar 

  23. Itoh K, Tilden AB, Balch CM (1986) Interieukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46:3011

    PubMed  CAS  Google Scholar 

  24. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1- transfected melanomas. J Immunol 148:638

    PubMed  CAS  Google Scholar 

  25. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487

    Article  PubMed  CAS  Google Scholar 

  26. Zemmour J, Parham P (1993) HLA Class I nucleotide sequences, 1992. Immunobiology 187:70

    Article  PubMed  CAS  Google Scholar 

  27. Bjorkman PJ, Parham P (1990) Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59:253

    Article  PubMed  CAS  Google Scholar 

  28. Van der Bmggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643

    Article  PubMed  Google Scholar 

  29. Chen Y-T, Stockert E, Tsang S, Coplan KE, Old LJ (1995) Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sei USA 92:8125

    Article  CAS  Google Scholar 

  30. Marincola FM, Hijazi YM, Fetsch P, Saigaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA (1996) Analysis of expression of the melanoma associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 19:192

    Article  CAS  Google Scholar 

  31. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM (1998) Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517)

    Article  PubMed  CAS  Google Scholar 

  32. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL (1998) Comparative analysis of the in vivo expression of tyrosinase, MART-l/Melan-A, and gp 100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother. 21:27

    Article  PubMed  CAS  Google Scholar 

  33. Fetsch PA, Kleiner D, Marincola FM, Abati A (1997) Analysis of melanoma associated antigen MART-1 in normal tissues and in selected non-melanomatous neoplasms. Modem Path 10:43

    Google Scholar 

  34. Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G (1994) Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B vims. J.ImmunoL 152:3074

    PubMed  CAS  Google Scholar 

  35. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, WiUiamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914

    Article  PubMed  CAS  Google Scholar 

  36. Marincola FM, Shamamian P, Rivoltini L, Salgaller ML, Reid J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR (1996) HLA associations in the anti-tumor response against malignant melanoma. J Immunother 18:242

    Article  Google Scholar 

  37. Player MA, Barracchini KC, Simonis TB, Rivoltini L, Arienti F, Castelli C, Mazzoc- chi A, Belli F, Marincola FM (1996) Differences in frequency distribution of HLA- A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination. J Immunother 19:357

    Article  CAS  Google Scholar 

  38. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515

    Article  PubMed  CAS  Google Scholar 

  39. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP et al (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 180:35

    Article  PubMed  CAS  Google Scholar 

  40. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458

    Article  PubMed  CAS  Google Scholar 

  41. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer KH zum Buschenfelde, and Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759

    Article  PubMed  CAS  Google Scholar 

  42. Van der Bmggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038

    Article  Google Scholar 

  43. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglu- cosaminyltransferase V gene. J Exp Med 183:1173

    Article  PubMed  CAS  Google Scholar 

  44. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Naguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against Cancer-Testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265

    Article  PubMed  CAS  Google Scholar 

  45. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2- restricted tumor infiltrating lymphocytes. J Exp Med 180:347

    Article  PubMed  CAS  Google Scholar 

  46. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 55:4972

    PubMed  CAS  Google Scholar 

  47. Nicotra MR, Nistico P, Mangoni A, Di Filippo F, Marincola FM, Natali PG (1997) Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J Immunother. 20:466

    Article  PubMed  CAS  Google Scholar 

  48. Kim CJ, Chan CH, Rosenberg SA (1998) Ophtalmologic evaluation in patients undergoing immunization with melanoma associated antigens. J. Immunother (in press)

    Google Scholar 

  49. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A (1995) Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685

    PubMed  Google Scholar 

  50. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM (1996) Binding and presentation of peptides derived from melanoma antigens MART-1 and gp 100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol 156:3882

    PubMed  CAS  Google Scholar 

  51. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio MF, Kubo RT, Chesnut RW, Sette A (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 45:79

    Article  PubMed  CAS  Google Scholar 

  52. Rotzschke O, Falk K, Stevanovic S, Jung G, Rammensee HG (1992) Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 22:2453

    Article  PubMed  CAS  Google Scholar 

  53. Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM (1997) Dendritic cells infected with poxviruses encoding MART-1/ MelanA sensitize T lymphocytes in vitro. J Immunother 20:276

    Article  PubMed  CAS  Google Scholar 

  54. Kim CJ, Parkinson DR, Marincola FM (1998) Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother 21(1): 1–16

    Article  PubMed  Google Scholar 

  55. Bettinotti M, Kim CJ, Lee K-H, Roden M, Cormier JN, Panelli MC, Parker KC, Marincola FM (1998) Stringent allele/epitope requirements for MART-l/Melan A immunodominance: implications for peptide-based inmiunotherapy. J Immunol 161: 877–889

    PubMed  CAS  Google Scholar 

  56. Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL, Jr (1996) Shared epitopes for HLA-A3- restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gplOO. J Immunol 157:5027

    PubMed  CAS  Google Scholar 

  57. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF (1995) Identification of a tyrosinase epitope recognized by HLA-A24- restricted, tumor-infiltrating lymphocytes. J Immunol 155:1343

    PubMed  CAS  Google Scholar 

  58. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethe B (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224

    Article  PubMed  CAS  Google Scholar 

  59. Gaugler B, Van den Eynde B, van der Bmggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921

    Article  PubMed  CAS  Google Scholar 

  60. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961

    PubMed  CAS  Google Scholar 

  61. Vitiello A, Ishioka G, Grey HM, Rose R, Famess P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R et al (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HB V infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341

    Article  PubMed  CAS  Google Scholar 

  62. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271

    Article  PubMed  CAS  Google Scholar 

  63. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7

    Article  PubMed  CAS  Google Scholar 

  64. Zitvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, and Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines [see comments]. J Exp Med 183:87

    Article  PubMed  CAS  Google Scholar 

  65. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr (1996) Peptide- pulsed dendritic cells induce antigen-specific CTL- mediated protective tumor immunity. J Exp Med 183:283

    Article  PubMed  CAS  Google Scholar 

  66. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317

    Article  PubMed  CAS  Google Scholar 

  67. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297

    Article  PubMed  CAS  Google Scholar 

  68. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony- stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109

    Article  PubMed  CAS  Google Scholar 

  69. Scher RL, Koch WM, W.J. Richtsmeier (1993) Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma. Arch Otolaryngol Head Neck Surg 119:432

    Article  PubMed  CAS  Google Scholar 

  70. Fuchs EJ, Matzinger P (1996) Is cancer dangerous to the immune system? Semin.Immunol. 8:271

    Article  PubMed  CAS  Google Scholar 

  71. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O’Shea JJ, Powers GC, Urba WJ, Ochoa AC (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327

    PubMed  CAS  Google Scholar 

  72. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Rosenberg SA, Yang JC (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731

    Article  PubMed  CAS  Google Scholar 

  73. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bomand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J (1996) Melanoma cell expression of Fas (Apo-l/CD95) ligand: Implications for tumor immune escape. Science 274:1363

    Article  PubMed  CAS  Google Scholar 

  74. Wojtowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165

    Article  PubMed  CAS  Google Scholar 

  75. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799

    Article  PubMed  CAS  Google Scholar 

  76. Castelli C, WJ Storkus, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 181:363

    Article  PubMed  CAS  Google Scholar 

  77. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716

    Article  PubMed  CAS  Google Scholar 

  78. Visseren MJW, van Elsas A, van der Voort EIH, Ressing MA, Kast WM, Schrier PI, and MeliefJM (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991

    PubMed  CAS  Google Scholar 

  79. Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF (1994) A decapeptide from human melanoma is recognized by CTL in melanoma patients. J Immunol 153:5650

    PubMed  CAS  Google Scholar 

  80. Van der Brüggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur J Immunol 24:2134

    Article  PubMed  Google Scholar 

  81. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, and van der Brüggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167

    Article  PubMed  CAS  Google Scholar 

  82. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689

    Article  PubMed  Google Scholar 

  83. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 183:1131

    Article  PubMed  CAS  Google Scholar 

  84. Rubinfeld B, Robbins P, el-Gamil M, Albert I, Porfiri E, Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790

    Article  PubMed  CAS  Google Scholar 

  85. Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma- specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. F. M. Marincola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Ronseberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cencer Center, Cepartment of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

  2. Pitié-Salpétrière Hospital, SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag France

About this paper

Cite this paper

Marincola, F.M., Ronseberg, S.A. (1999). The Development of Cancer Vaccines for the Treatment of Metastatic Melanoma. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0918-2_11

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59666-7

  • Online ISBN: 978-2-8178-0918-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation